(NP (NP (NN Lack)) (PP (IN of) (NP (NP (JJ T-cell-mediated) (NN recognition)) (PP (IN of) (NP (NP (DT the) (NN fusion) (NN region)) (PP (IN of) (NP (DT the) (NN (RAR-alpha pml)) (NN hybrid) (NN protein))))) (PP (IN by) (NP (NP (NNS lymphocytes)) (PP (IN of) (NP (JJ acute) (JJ promyelocytic) (NN leukemia) (NNS patients))))))) (. .))
(S (PP (IN In) (NP (JJ previous) (NNS studies))) (, ,) (NP-SBJ (PRP it)) (VP (VBD was) (VP (VBN shown) (SBAR (IN that) (S (NP-SBJ-42 (NP (DT the) (NN fusion) (NN region)) (PP (IN of) (NP (DT the) (NN (RAR-alpha pml)) (NN protein))) (, ,) (VP (VBN expressed) (NP (-NONE- *)) (PP (IN by) (NP-LGS (NP (NP (JJ acute) (JJ promyelocytic) (NN leukemia)) (PRN (-LRB- -LRB-) (NP (NN APL)) (-RRB- -RRB-))) (NNS cells)))) (, ,)) (VP (MD can) (VP (VB be) (VP (ADVP (RB specifically)) (VBN recognized) (NP (-NONE- *-42)) (ADVP (FW in) (FW vitro)) (PP (IN by) (NP-LGS (NP (NP (NN donor)) (PRN (-LRB- -LRB-) (NP (NNP D.) (NNP E.)) (-RRB- -RRB-))) (NN CD4) (NN T) (NNS cells))) (PP (IN in) (NP (DT a) (ADJP (NN HLA) (NN class) (CD II) (JJ DR11-restricted)) (NN fashion)))))))))) (. .))
(S (NP-SBJ (PRP We)) (VP (VBP present) (ADVP (RB here)) (NP (NP (DT the) (NNS results)) (PP (IN on) (NP (NP (DT the) (NN recognition)) (PP (IN of) (NP (JJ several) (NN (RAR-alpha pml)) (NNS peptides))) (PP (IN by) (NP (NP (NN APL) (NNS patients)) (VP (VBG expressing) (NP (NN HLA) (NN DR11))))))))) (. .))
(S (NP-SBJ (NP (DT The) (ADJP (FW in) (FW vitro)) (NN immunization)) (PP (IN of) (NP (NP (JJ peripheral) (NN blood) (NNS lymphocytes)) (PP (IN from) (NP (NP (NP (CD four) (NNS patients)) (PP (IN in) (NP (NN remission)))) (PRN (-LRB- -LRB-) (NP-COOD (NP (NNP S.R.)) (, ,) (NP (NNP F.R.)) (, ,) (NP (NNP M.M.)) (, ,) (NP (NNP P.) (NNP G.))) (-RRB- -RRB-)))))) (PP (IN with) (NP (NP (NN (25 BCR1))) (, ,) (NP (DT a) (NN 25-mer) (NN (RAR-alpha pml))) (, ,)))) (VP (VBD did) (RB not) (VP (VB elicit) (NP (NP (NP-COOD (CC either) (NP (DT a) (JJ polyclonal) (NP (-NONE- *RNR*-43))) (CC or) (NP (DT a) (JJ clonal) (NP (-NONE- *RNR*-43)))) (NP-43 (JJ immune) (NN response))) (ADJP (JJ specific) (PP (TO to) (NP (DT the) (NN peptide))))))) (. .))
(S (NP-SBJ (PRP We)) (ADVP-TMP (RB then)) (VP (VBD generated) (NP (JJ new) (NN donor) (JJ (RAR-alpha anti-pml)) (JJ CD4-LRB-+-RRB-) (NN T-cell) (NNS clones))) (. .))
(S (NP-SBJ-44 (DT These) (NNS clones)) (VP (VBD were) (VP (VBN tested) (NP (-NONE- *-44)) (PP (IN for) (NP (NP (PRP$ their) (NN recognition)) (PP (IN of) (NP (NN (25 BCR1)))))))) (. .))
(S (NP-SBJ-45 (NP (CD One) (NN clone)) (PRN (-LRB- -LRB-) (NP (NP (NN (5 C3))) (, ,) (ADJP-COOD (ADJP (JJ CD3-LRB-+-RRB-)) (, ,) (ADJP (JJ CD4-LRB-+-RRB-)) (, ,) (ADJP (JJ CD8-LRB---RRB-)))) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN selected) (NP (-NONE- *-45)) (PP (IN for) (NP (JJ further) (NN analysis))))) (. .))
(S (NP-SBJ-46 (NN Clone) (NN (5 C3))) (VP (VBD showed) (NP (JJ specific) (NP-COOD (NP (NN proliferation)) (, ,) (NP (NN cytotoxicity)) (, ,) (CC and) (NP (NP (NP (NN cytokine)) (PRN (-LRB- -LRB-) (NP (UCP-COOD (NP (NN tumor) (NN necrosis) (NN factor) (NN alpha)) (, ,) (ADJP (JJ granulocyte-macrophage) (JJ colony-stimulating))) (NN factor)) (-RRB- -RRB-))) (NN production)))) (SBAR-TMP (WHADVP-48 (WRB when)) (S (NP-SBJ-47 (-NONE- *-46)) (VP (VBN challenged) (NP (-NONE- *-47)) (PP (IN with) (NP (NP (JJ autologous) (JJ lymphoblastic) (NN cell) (NNS lines)) (VP (VBN pulsed) (NP (-NONE- *)) (PP (IN with) (NP (NN peptide) (NN (25 BCR1))))))) (ADVP (-NONE- *T*-48)))))) (. .))
(S (NP-SBJ-49 (NN (5 C3)) (NNS cells)) (VP (VBD developed) (NP (JJ specific) (NP-COOD (NP (NN proliferation)) (CC and) (NP (NN cytotoxicity)))) (SBAR-TMP (WHADVP-51 (WRB when)) (S (NP-SBJ-50 (-NONE- *-49)) (VP (VBN challenged) (NP (-NONE- *-50)) (PP (IN with) (NP (NP (JJ peptide-pulsed) (NP-COOD (NP (JJ lymphoblastic) (NN cell) (NNS lines)) (CC and) (NP (JJ peripheral) (NN blood) (NNS lymphocytes)))) (PP (IN from) (NP (DT the) (CD four) (JJ DR11-LRB-+-RRB-) (NN APL) (NNS patients))))) (ADVP (-NONE- *T*-51)))))) (. .))
(S (NP-SBJ-52 (NP (NN APL) (NNS blasts)) (, ,) (ADJP (JJ available) (PP (RB only) (IN from) (NP (NNS patients) (NP-COOD (NP (NNP F.R.)) (CC and) (NP (NNP P.G.)))))) (, ,)) (VP-COOD (VP (VBD were) (RB not) (VP (VBN lysed) (NP (-NONE- *-52)) (PP (IN by) (NP-LGS (NN (5 C3)))))) (CC and) (VP (VBD were) (ADJP-PRD (JJ unable) (S (NP-SBJ (-NONE- *-52)) (VP (TO to) (VP (VB present) (NP (NN peptide) (NN (25 BCR1))))))))) (. .))
(S (NP-SBJ-53 (NP (NN Incubation)) (PP (IN of) (NP (NN APL) (NNS cells))) (PP (IN with) (NP (NN IFN-gamma)))) (VP (VBD failed) (S (NP-SBJ (-NONE- *-53)) (VP (TO to) (VP (VB induce) (NP-COOD (NP (NN HLA) (NN class) (CD II) (NNS molecules)) (CC and) (NP (NP (NN recognition)) (PP (IN by) (NP (DT the) (NN (5 C3)) (NN clone))))))))) (. .))
(S (SBAR (IN Since) (S (NP-SBJ (NN APL) (NNS cells)) (VP (VBP do) (RB not) (VP (VB express) (NP (NN HLA) (NN class) (CD II) (NNS molecules)))))) (, ,) (NP-SBJ (PRP we)) (VP (VBD tested) (PP-COOD (PP (IN in) (NP (NP (CD two) (NNS donors)) (PRN (-LRB- -LRB-) (NP-COOD (NP (NNP D.E.)) (CC and) (NP (NNP C.H.R.))) (-RRB- -RRB-)))) (CC and) (PP (IN in) (NP (NNS patients) (NP-COOD (NP (NN S.R.)) (CC and) (NP (NN P.G.)))))) (SBAR (CC whether) (S (NP-SBJ (NP (DT the) (NN use)) (PP (IN of) (NP (NP (NN 9-mer) (NNS peptides)) (PRN (-LRB- -LRB-) (NP (NN (9 BCR1))) (-RRB- -RRB-))))) (VP (MD would) (VP (VB generate) (NP (DT a) (ADJP (NN (HLA CD8)) (NN class) (JJ I-restricted)) (NN response))))))) (. .))
(S (NP-SBJ-54 (DT No) (JJ peptide-specific) (NN T-cell) (NP-COOD (NP (NN line)) (CC or) (NP (NN clone)))) (VP (MD could) (VP (VB be) (VP (VBN generated) (NP (-NONE- *-54)) (PP (IN from) (NP-COOD (CC both) (NP (NNS donors)) (CC and) (NP (NNS patients))))))) (. .))
(S (NP-SBJ-55 (DT These) (NNS findings)) (VP (VBP are) (VP (VBN discussed) (NP (-NONE- *-55)) (PP (IN in) (NN relation) (TO to) (NP (NP (JJ possible) (JJ therapeutic) (NNS approaches)) (PP (TO to) (NP (NP (DT the) (NN immunotherapy)) (PP (IN of) (NP (NN APL))))))))) (. .))
